Actinium down on panel advice on Iomab-B trial

 

• Shares of Actinium Pharmaceuticals (NYSEMKT:ATNM) sunk 22% in morning trade after an Independent Data Monitoring Committee recommended (DMC) that its late-stage SIERRA trial should continue as planned to full enrollment of 150 patients.
• The trial tests the safety and effectiveness of Iomab-B for bone marrow transplant (BMT) conditioning in patients over the age of 55 with active relapsed or refractory Acute Myeloid Leukemia
• The SIERRA trial, which is currently over 75% enrolled, is a randomized, controlled study evaluating outcomes of patients receiving Iomab-B and a BMT compared to outcomes of patients on the control arm who receive physician's choice of salvage therapies, including recently approved targeting agents such as venetoclax, who may proceed to BMT if they achieve a required complete remission (CR).
• "We are encouraged by the DMC's recommendation to continue the SIERRA trial as planned and that there continues to be no safety concerns from the Iomab-B arm," Mark Berger, Actinium's Chief Medical Officer said.
• Earlier this month, Actinium had published encouraging interim data from the trial in the American Society of Hematology.
• https://seekingalpha.com/news/3647715-actinium-down-22-on-independent-data-monitoring-committee-recommendation-for-iomab-b-trial